Amicus Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amicus Therapeutics, Inc.
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Office of New Drugs director Peter Stein shed some light on how the newly established Division of Rare Diseases and Medical Genetics will operate following the completion of the OND reorganization, drawing mixed reactions from industry speakers.
The Alliance for Regenerative Medicine’s Q3 report illustrates just how far the sector has come in the 10 years since the organization’s founding. The number of therapies in the pipeline has ballooned, in parallel with financing for development activities.
A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Callidus Biopharma
- MiaMed, Inc.
- Scioderm, Inc.